Tezosentan in patients with acute heart failure and acute coronary syndromes: Design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4)

American Heart Journal

Volumn 145, Issue 2 SUPPL., 2003, Pages

  O'Connor, Christopher M ^a,e   Gattis, Wendy A ^a   Adams Jr , Kirkwood F ^b   Shah, Monica R ^a   Frey, Aline ^c   Gheorghiade, Mihai ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

^d NORTHWESTERN UNIVERSITY   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; TEZOSENTAN;

ACUTE HEART FAILURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EVALUATION; EXPERIMENTAL DESIGN; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; SAMPLE SIZE; STATISTICAL ANALYSIS;

EID: 0037323570     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.156     Document Type: Conference Paper

References (13)

1. Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T. Am Heart J 1999;138:95-9.
2. Chen YN, Wei JR, Zeng LJ, et al. Monitoring of cardiac troponin I in patients with acute heart failure. Ann Clin Biochem 1999;36:433-7.
3. Mossov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997;96:2953-8.
4. Del Carlo C, O'Connor CM. Cardiac troponins in congestive heart failure. Am Heart J 1999;138:646-53.
5. Setsuta K, Seino Y, Takahashi N, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999;84:608-11.
6. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
7. Love MP, McMurray JJV. Endothelin in chronic heart failure: current position and future prospects. Cardiovasc Res 1996;31:665-74.
8. Sharma R, Coats AJS, Anker SD. The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. Int J Cardiol 2000;72:175-86.
9. Love MP, Haynes WG, Webb DJ, et al. Venous endothelin receptor function in patients with chronic heart failure. Clin Science 2000;98:65-70.
10. Pousset F, Isnard R, Lechat P, et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997;18:254-8.
11. Sutsch G, Kiowski W, Yan XW, et al. Short term oral endothelin receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998;98;2262-8.
12. Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353-5.
13. O'Connor CM, Gattis WA, Adams KF, et al. Tezosentan in patients with acute heart failure and acute coronary syndrome: design of the Randomized Intravenous Tezosentan Study (RITZ-4). Am Heart J 2002;144:583-8.